Anaesthesia for noncardiac surgery in the heart transplant recipient

Current Opinion in Anaesthesiology

Volumn 22, Issue 1, 2009, Pages 109-113

  Blasco, Lucrecia María ^a   Parameshwar, Jayan ^a   Vuylsteke, Alain ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Anaesthesia; Cardiac transplantation; Immunosuppression

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MUSCLE RELAXANT AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PANCURONIUM; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VASOACTIVE AGENT; VECURONIUM;

ANESTHESIA; BLOOD VESSEL TONE; BONE MARROW SUPPRESSION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG POTENTIATION; GASTROINTESTINAL DISEASE; GRAFT INFECTION; GRAFT RECIPIENT; HEART PRELOAD; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION RISK; KIDNEY DISEASE; MALIGNANT NEOPLASTIC DISEASE; OSTEOPOROSIS; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANESTHESIA; HEART; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; SURGICAL PROCEDURES, OPERATIVE;

EID: 62249165783     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32831c83e0     Document Type: Review

References (38)

1. Klein DG. Current trends in cardiac transplantation. Crit Care Nurs Clin North Am 2007; 19:445-460; vii.
2. Bjerke R, Mangione M. Asystole after intravenous neostigmine in a heart transplant recipient. Can J Anaesth 2001; 48:305-307.
3. Bengel F, Ueberfuhr P, Schiepel N, et al. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. New Engl J Med 2001; 345:731-738.
4. Allard R, Hatzakorzian R, Deschamps A. Decreased heart rate and blood pressure in a recent cardiac transplant patient after spinal anesthesia. Can J Anesth 2004; 51:829-833.
5. Cheng DCH, Ong DD. Anaesthesia for noncardiac surgery in heart-trans-planted patients. Can J Anaesth 1993; 40:981-986. This classic manuscript describes anaesthesia in heart recipients.
6. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 2006; 25:869-879.
7. Fazel S, Everson A, Stitt LW, et al. Predictors of general surgical complications after heart transplantation. J Am Coll Surg 2001; 193:52.
8. Marzoa R, Crespo-Leiro MG, Paniagua MJ, et al. Late noncardiac surgery in heart transplant patients. Transplant Proc 2007; 9:2382-2384. A useful source listing most common indications and complications of noncardiac surgery in heart transplant patients.
9. Tan CD, Baldwin WM 3rd, Rodriguez ER. Update on cardiac transplantation pathology. Arch Pathol Lab Med 2007; 131:1169-1191.
10. Hiemann NE, Knosalla C, Wellnhofer E, et al. Quilty in biopsy is associated with poor prognosis after heart transplantation. Transpl lmmunol 2008; 19:209-214.
11. Hiemann NE, Knosalla C, Wellnhofer E, et al. Quilty indicates increased risk for microvasculopathy and poor survival after heart transplantation. J Heart Lung Transplant 2008; 27:289-296.
12. Hsieh GR, Schnickel GT, Garcia C, et al. Inflammation/oxidation in chronic rejection: apolipoprotein a-l mimetic peptide reduces chronic rejection of transplanted hearts. Transplantation 2007; 84:238-243.
13. Kobashigawa JA, Patel JK. lmmunosuppression for heart transplantation: where are we now? Nat Clin Pract Cardiovasc Med 2006; 3:203-212.
14. Celik S, Doesch A, Erbel C, et al. Beneficial effects of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 2008; 86:245-250. This article showed good results with diet in order to prevent hypertriglyceridaemia and protect against cardiac allograft vasculopathy.
15. Mehra M, Uber P, Walther D, et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation. Circulation 2006; 114 (Suppl l):l-21-l-26.
16. Gustafsson F, Ross H. Proliferation signal inhibitors in cardiac transplantation. Curr Opin Cardiol 2007; 22:111-116. This is the most recent and interesting article about these new drugs and their effects and side effects.
17. Aqel RA Wells Bj, Hage FG. Re-stenosis after drug-eluting stents in cardiac allograft vasculopathy. J Heart Lung Transplant 2008; 27:610-615; Epub 2008.
18. Agiiero J, Almenar L, Martinez-Dolz L, et al. Influence of immunosuppressive regimens on short-term morbidity and mortality in heart transplantation. Clin Transplant 2008; 22:98-106.
19. Van de Beek D, Kremers WK, del Pozo JL, et al. Effects of infectious diseases on outcome after heart transplant. Mayo Clinic Proc 2008; 83:304-308. Infection is a major cause of morbidity and mortality in the heart transplant population.
20. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with the novo sirolimus versus MMF-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6:986-992.
21. Al-khaldi A, Robbins RC. New directions in cardiac transplantation. Annu Rev Med 2006; 57:455-471.
22. Fearon WF, Potena L, Hirohata A, et al. Changes in coronary arterial dimensions early after cardiac transplantation. Transplantation 2007; 83: 700-705.
23. Yamani MH, Taylor DO, Czerr J, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant 2008; 22:76-81.
24. Crespo-Leiro MG, Paniagua MJ, Franco R, et al. Late steroid withdrawal after heart transplantation and incidence of acute rejection. Transplant Proc 2007; 39:2372-2374.
25. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80:883-889.
26. Woodside KJ, Lick SD. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant 2007; 26:750-752.
27. Eisen HJ. Immunosuppression on the horizon. Heart Fail Clin 2007; 3:43-49.
28. Aliabadi AZ, Zuckermann AO, Grimm M. Immunosuprresive therapy in older cardiac transplant patients. Drug Aging 2007; 24:913-932.
29. Kostopanagiotou G, Smyrniotis V, Arkadopoulos N, et al. Anesthetic and perioperative management of adult transplant recipient in nontransplant surgery. Anesth Analg 1999; 89:613-622.
30. Saeed I, Rogers C, Munday A, Steering Group of the UK Cardiothoracic Transplant Audit. Health-related quality of life after cardiac transplantation: results of a UK National Survey with norm-based comparisons. J Heart Lung Transplant 2008; 27:675-681. A good exposé of quality of life and comorbidity after transplant.
31. Thorn EM, de Filipi CR. Echocardiography in the cardiac transplant recipient. Heart Fail Clin 2007; 3:51-67.
32. Shaw SM, Fildes J, Yonan N, Williams SG. Does brain natriuretic peptide interact with the immune system after cardiac transplantation? Transplantation 2007; 84:1377-1381.
33. Almenar L, Martínez-Dolz L, Moro J. Natriuretic peptides and heart transplant. Curr Opin Mol Ther 2007; 9:282-290.
34. Park MH, Uber PA, Scott RL, Mehra MR. B-type natriuretic peptide in heart transplantation: an important marker of allograft performance. Heart Fail Rev 2003; 8:359-363.
35. O'Neill JO, McRae AT 3rd, Troughton RW, et al. Brain natriuretic peptide levels do not correlate with acute cellular rejection in de novo orthotopic heart transplant recipients. J Heart Lung Transplant 2005; 24:416-420.
36. Beiras-Fernandez A, Weis FC, Fuchs H, et al. Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery? Transplantation 2006; 82:1101-1103.
37. Beiras-Fernández A, Weis FC, Kur F, et al. Primary graft failure and Ca++ sensitizers after heart transplantation. Transplant Proc 2008; 40:951-952.
38. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 2007; 83:1525-1535.